Oncotarget - podcast cover

Oncotarget

Oncotarget Podcastwww.oncotarget.com
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed. Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed. Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Last refreshed:
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Download Metacast podcast app
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer

Dr. Glenn Simmons Jr. from Cornell University College of Veterinary Medicine, and Dr. Stefani Thomas from University of Minnesota School of Medicine, detail a recent review they co-authored that was published by Oncotarget, entitled, “Targeting lipid metabolism in the treatment of ovarian cancer.” DOI - https://doi.org/10.18632/oncotarget.28241 Correspondence to - Glenn E. Simmons Jr. - glenn.simmons@cornell.edu Video version - https://www.youtube.com/watch?v=RCvzLXZM1-A Abstract Cancer cells un...

Sep 12, 20228 min

Press Release: Imaging With Polypeptide Fusion Protein Targets Bladder Cancer

Listen to a press release about a new research paper published by Oncotarget, entitled, “Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.” _______________________________ A new research paper was published in Oncotarget on September 6, 2022, entitled, “Targeted elastin-like polypeptide fusion protein for near-infrared imaging of human and canine urothelial carcinoma.” Bladder cancer (BC) is the 10th most common malignancy, affec...

Sep 08, 20225 min

Immunotherapy Response Predicted By Machine Learning & Gut Microbiomes

Listen to a blog summary of a recent research paper published by Oncotarget, entitled, "Immunotherapy Response Predicted by Machine Learning & Gut Microbiomes." __________________________________________ Immunotherapy has become a powerful breakthrough in cancer treatment, however, 50% of patients do not respond to immunotherapy. What internal or external features inhibit or confer patient or tumor response to immune system-harnessing therapeutics? These patient/tumor features that impact re...

Sep 01, 20227 min

Epigenetics and Immunotherapy Combined Fights Rare Lymphoma

Listen to a blog summary of a recent research paper published by Oncotarget, entitled, "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma." __________________________________________ Mantle cell lymphoma (MCL) is a type of non-Hodgkin’s lymphoma (NHL) that is aggressive, difficult to treat and typically affects older adults. Recurrence and mortality rates among patients with MCL have remained high, despite recent therapeutic advances. Blastic mantle cell lympho...

Aug 24, 20227 min

Press Release: Kinase Activity in RCC, Renal Tissue and in Response to TKI

A new research paper was published in Oncotarget on August 4, 2022, entitled, “Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors.” Kinase activity is frequently altered in renal cell carcinoma (RCC), and tyrosine kinase inhibitors (TKIs) are part of the standard treatment strategy in patients with metastatic disease. However, there are still no established biomarkers to predict clinical benefits of a specific TKI. ...

Aug 17, 20224 min

Glypican-3 (GPC3) Associated With MCPyV-negative Status and Impaired Outcome in MCC

A new research paper was published in Oncotarget on August 3, 2022, entitled, “Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.” Merkel cell carcinoma (MCC) is an aggressive skin cancer, related to the Merkel Cell Polyomavirus (MCPyV) in 80% of cases. Immune checkpoint inhibitors provide sustained benefit in about 50% of MCC patients with advanced disease. Glypican-3 (GPC3) is an oncofetal tumor antigen that is an attractive target for chi...

Aug 11, 20225 min

Press Release: Novel Regulatory Mechanism of GLI3 by Toll-like Receptor Signaling

A new research paper was published in Oncotarget on August 3, 2022, entitled, “A novel mechanism of regulation of the oncogenic transcription factor GLI3 by toll-like receptor signaling.” The transcription factor GLI3 is a member of the GLI family and has been shown to be regulated by canonical hedgehog (HH) signaling through smoothened (SMO). Little is known about SMO-independent regulation of GLI3. “Hedgehog (HH) signaling is well known for its role in embryonic development, cancer and inflamm...

Aug 09, 20225 min

Does a Mechanism Linking Cellular Aging to Cellular Quiescence Exist?

Listen to a blog summary of a trending research paper published by Oncotarget on July 28, 2022, entitled, "Diverse geroprotectors differently affect a mechanism linking cellular aging to cellular quiescence in budding yeast." ______________________________________ The mechanisms of cellular aging and cellular quiescence have been preserved throughout evolution. Cellular quiescence is a temporary state of cell cycle arrest and low metabolic activity. Importantly, quiescent (Q) cells maintain the ...

Aug 08, 202211 min

Press Release: Chemoradiation Alters PD-L1, CD8+ TILs and Mucin in Rectal Cancer

A new research paper was published in Oncotarget on July 28, 2022, entitled, “Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.” DNA damage and resulting neoantigen formation is considered a mechanism for synergy between radiotherapy and PD-1/PD-L1 pathway inhibition to induce antitumor immune response. In a new research study, by Marina Baretti, Qingfeng Zhu, Wei Fu, Jeffrey Meyer, Hao Wang, Robert A. Ander...

Aug 02, 20226 min

Press Release: CUDC907 Promotes Apoptosis Of NF2 Schwannoma Cells

A new research paper was published in Oncotarget on July 19, 2022, entitled, “CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.” Neurofibromatosis Type 2 (NF2) is a rare tumor disorder caused by pathogenic variants of the merlin tumor suppressor encoded by NF2. Patients develop vestibular schwannomas (VS), peripheral schwannomas, meningiomas, and ependymomas. There are no approved drug therapies for NF2. Previous work identified ...

Jul 26, 20226 min

Predicting Cancer Immunotherapy Response From Gut Microbiomes Using Machine Learning Models

Listen to the press release about a new research paper published in Volume 13 of Oncotarget, “Predicting cancer immunotherapy response from gut microbiomes using machine learning models.” ___________________________________ A new research paper was published in Oncotarget on July 19, 2022, entitled, “Predicting cancer immunotherapy response from gut microbiomes using machine learning models.” “In the last decade, the use of cancer immunotherapy targeting immune checkpoint inhibitors (ICIs) to bo...

Jul 20, 20225 min

How Heartburn Can Turn Into Esophageal Cancer, and a Possible Biomarker

Listen to a blog summary of a trending research paper published in Volume 13 of Oncotarget, entitled, "Telomere shortening accelerates tumor initiation in the L2-IL1B mouse model of Barrett esophagus and emerges as a possible biomarker." ___________________________________ Smokers are significantly more likely than nonsmokers to have acid reflux. In many Western countries, a popular diet—known for its convenience, availability and, frankly, its lack of nutritional value—is also known to cause ac...

Jul 15, 20228 min

Behind the Study: Molecular Characterization of Lung Carcinomas Expressing KK-LC-1

Dr. Robert Hsu from the Department of Internal Medicine, Division of Medical Oncology, Norris Comprehensive Cancer Center and Hospital, University of Southern California, describes a recent research paper he co-authored that was published by Oncotarget, entitled, “Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.” DOI - https://doi.org/10.18632/oncotarget.28132 Correspondence to - Jorge J. Nieva - jorge.nieva@med.usc.edu Abstract Cancer/testis antigen...

Jul 11, 20226 min

Role Of Germline Variants In The Metastasis Of Breast Carcinomas

A new research paper was published in Oncotarget on June 30, 2022, entitled, “Role of germline variants in the metastasis of breast carcinomas.” Most cancer-related deaths in breast cancer patients are associated with metastasis, a multistep, intricate process that requires the cooperation of tumor cells, tumor microenvironment and metastasis target tissues. It is accepted that metastasis does not depend on the tumor characteristics but the host’s genetic makeup. “However, there has been limited...

Jul 07, 20225 min

Press Release: Continuous Treatment With Abemaciclib and Breast Cancer Cell Proliferation

Researchers from Eli Lilly and Company published a new research paper in Oncotarget on July 2, entitled, “Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.” Worldwide, breast cancer (BC) is the second most common cancer. Pharmacologically targeting cyclin-dependent kinase 4 and 6 (CDK4 & 6) has proven to be a successful therapeutic approach in patients with estrogen receptor-positive (ER+) breast cancer. Abemaciclib is the ...

Jul 06, 20224 min

Genes & Cancer: How Ewing Sarcoma Led to Discoveries in Rhabdomyosarcoma

Listen to a blog summary of a research paper published by Genes & Cancer, entitled, "KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.” Rhabdomyosarcoma (RMS) and Ewing Sarcoma are among the most common types of cancer that develop in childhood. In recent years, new studies from researchers at the University of Colorado Denver Anschutz Medical Campus have contributed to the expansion of biomedical knowledge about how these diseases progress—paving a way for ...

Jun 29, 20228 min

Press Release: New Oncology-Focused Papers Published in Volume 13

At the start of 2022, Oncotarget began publishing research papers in a continuous publishing format in yearly volumes. As of June 23, 2022, Oncotarget has published a total of 64 high-impact, oncology-focused papers within Volume 13. Oncotarget’s Volume 13 consists of papers authored by numerous prestigious researchers and scientists from world-renowned institutions. Select papers in this Volume were chosen for inclusion in Oncotarget’s Special Collections on breast and lung cancer research. Rea...

Jun 23, 202215 min

Press Release: Genes & Cancer | Now on PubMed: Volume 12

BUFFALO, NY- June 16, 2022 – Oncology-focused research papers published in Volume 12 of Genes & Cancer are now on PubMed. Read short previews about some of the groundbreaking studies published in 2021 by Genes & Cancer. Visit YouTube to watch video previews of studies published by Genes & Cancer. Full press release - https://www.impactjournals.com/journals/blog/genesandcancer/genes-cancer-now-on-pubmed-volume-12/ About Genes & Cancer: Genes & Cancer covers all aspects of the ...

Jun 17, 20228 min

Press Release: Impact Journals Sponsors 2022 Ride for Roswell

The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 26 years to celebrate cancer survivors, pay tribute to lives that have been lost, and to work together to support research and find a cure. When it opened its doors in Buffalo in 1898, Roswell Park Comprehensive Cancer Center w...

Jun 15, 20225 min

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.” DOI - https://doi.org/10.18632/oncotarget.28202 Correspondence to - Jeffrey A. Borgia - jeffrey_a_borgia@rush.edu Abstract Background: Detection rates of early-stage lung cancer are traditionally low, which contributes to inco...

Jun 14, 20225 min

Press Release: Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified ...

BUFFALO, NY- June 8, 2022 – A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.” Breast cancer (BC) is the most common type of cancer diagnosed in women. Among female cancer deaths, BC is the second leading cause of death worldwide. For estrogen receptor-positive (ER-positive) breast cancers, endocrine therapy is an effective therapeutic approach. However, in many...

Jun 08, 20224 min

Paper Spotlight: Tool Uses NF-κB Activity to Classify HPV+ Head and Neck Cancer

Listen to a blog summary of a trending research paper published in Volume 13, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” ______________________________ Over the last 10 years in the United States, the human papillomavirus (HPV) has caused more head and neck squamous cell carcinomas (HNSCC) than uterine cervical cancers. Primarily caused either by exposure to HPV or to ethanol or tobacco, HNSCC is a disease that impairs fundamental tissues...

May 26, 20227 min

Press Release: NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

BUFFALO, NY- May 25, 2022 – A new research paper was published in Oncotarget, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” Head and neck squamous cell carcinoma (HNSCC) is a devastating disease that impairs fundamental tissues involved in respiration, phonation and digestion. HNSCC is primarily caused by exposure to either ethanol and tobacco or the human papillomavirus (HPV). Among patients with HPV+ HNSCC, there is a growing clinical dema...

May 25, 20224 min

Press Release: Anti-Cancer Drug Profiling With CancerOmicsNet

BUFFALO, NY- May 19, 2022 – A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.” Researchers from Louisiana State University developed CancerOmicsNet—a graph neural network model to predict the growth rate of a cancer cell line after drug treatment. “CancerOmicsNet is more advanced than many deep learning techniques operating in the Euclidean space [47], because it extracts knowledge directl...

May 20, 20224 min

Trending With Impact: Dual Requirement in Stem Cell Leukemia/Lymphoma

Listen to a blog summary of a trending research paper published by Oncotarget, entitled, "Proteomic analysis reveals dual requirement for Grb2 and PLCγ1 interactions for BCR-FGFR1-Driven 8p11 cell proliferation." ___________________________________________ Chromosomes are found in the nucleus of cells and consist of proteins and tightly coiled strands of DNA. During cell division, chromosomal translocations can occur while the chromosomes are being copied. This type of mutation can mean that an ...

May 18, 20227 min

Press Release: Impact Journals at SSP Annual Meeting

BUFFALO, NY-May 16, 2022 – Impact Journals (based out of Buffalo, New York) is an international open-access publisher of journals in the field of biomedical sciences. Impact Journals is on a mission to provide scientists with the opportunity to share exceptional discoveries, offer services that enable rapid dissemination of results, and present vital findings from the many fields of biomedical science. This mission cannot be accomplished without following strong ethical standards. Scientific int...

May 18, 20222 min

Paper Spotlight: Gene Variants Investigated in Polish Bladder and Kidney Cancer

Listen to a blog summary of a research paper published by Oncotarget in Volume 13, entitled, "Bladder cancer survival in patients with NOD2 or CDKN2A variants.” _______________________________ Genitourinary cancers are a group of cancers that affect components of the urinary tract, including the bladder and kidneys. Worldwide, bladder and kidney cancer impact men at disproportionately higher rates than women. While incidence and mortality rates of bladder cancer in most western European countrie...

Apr 28, 20227 min

Trending With Impact: Analysis of Mutational Burden in NSCLC

Listen to a blog summary of a trending research paper published by Oncotarget in Volume 13, entitled, "Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study." ___________________________________ While a high tumor mutational burden (TMB) may seem unfavorable in the midst of battling non-small cell lung cancer (NSCLC), a higher TMB has been associated with a higher number of neoantigens. The presence of more neoantigens can potentially elici...

Apr 26, 20228 min

Press Release: Mutational Burden in Lung Cancer Studied in Multisite Cohort

BUFFALO, NY-April 25, 2022 – A new research paper, entitled, “Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study,” was published in Oncotarget on January 31, 2022, by researchers from University of Utah, University of Minnesota Duluth, Huntsman Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, Baptist Health Medical Group, MetroHealth Medical Center, Rutgers Cancer Institute of New Jersey, University of Southern Cali...

Apr 26, 20224 min

Author Insight: How ONC201 Kills Breast Cancer Cells

Dr. Stanley Lipkowitz and Dr. Yoshimi Endo Greer from the Women’s Malignancies Branch at the National Cancer Institute discuss a research paper they co-authored that was published by Oncotarget in 2018, entitled, "ONC201 kills breast cancer cells in vitro by targeting mitochondria." DOI - https://doi.org/10.18632/oncotarget.24862 Correspondence to - lipkowis@mail.nih.gov Abstract We report a novel mechanism of action of ONC201 as a mitochondria-targeting drug in cancer cells. ONC201 was original...

Apr 22, 202213 min
For the best experience, listen in Metacast app for iOS or Android